Sutro Biopharma (STRO) Revenue & Revenue Breakdown
Sutro Biopharma Revenue Highlights
Latest Revenue (Y)
$153.73M
Latest Revenue (Q)
$13.01M
Main Segment (Y)
Collaboration Revenue
Main Geography (Y)
Collaboration Revenue
Sutro Biopharma Revenue by Period
Sutro Biopharma Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $153.73M | 126.84% |
| 2022-12-31 | $67.77M | 9.52% |
| 2021-12-31 | $61.88M | 44.84% |
| 2020-12-31 | $42.72M | -0.03% |
| 2019-12-31 | $42.74M | 11.24% |
| 2018-12-31 | $38.42M | -25.75% |
| 2017-12-31 | $51.74M | -13.38% |
| 2016-12-31 | $59.73M | - |
Sutro Biopharma generated $153.73M in revenue during NA 2023, up 126.84% compared to the previous quarter, and up 400.14% compared to the same period a year ago.
Sutro Biopharma Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $13.01M | -88.56% |
| 2023-12-31 | $113.72M | 571.95% |
| 2023-09-30 | $16.92M | 62.54% |
| 2023-06-30 | $10.41M | -17.85% |
| 2023-03-31 | $12.67M | 46.83% |
| 2022-12-31 | $8.63M | -65.67% |
| 2022-09-30 | $25.15M | -10.50% |
| 2022-06-30 | $28.10M | 376.45% |
| 2022-03-31 | $5.90M | -44.65% |
| 2021-12-31 | $10.65M | 25.09% |
| 2021-09-30 | $8.52M | -69.64% |
| 2021-06-30 | $28.05M | 91.33% |
| 2021-03-31 | $14.66M | 77.10% |
| 2020-12-31 | $8.28M | -53.55% |
| 2020-09-30 | $17.82M | 88.22% |
| 2020-06-30 | $9.47M | 32.40% |
| 2020-03-31 | $7.15M | -36.74% |
| 2019-12-31 | $11.30M | -7.92% |
| 2019-09-30 | $12.28M | 16.65% |
| 2019-06-30 | $10.53M | 21.97% |
| 2019-03-31 | $8.63M | -54.79% |
| 2018-12-31 | $19.09M | 143.57% |
| 2018-09-30 | $7.84M | 37.38% |
| 2018-06-30 | $5.70M | -1.54% |
| 2018-03-31 | $5.79M | 43.39% |
| 2017-12-31 | $4.04M | -76.91% |
| 2017-09-30 | $17.50M | 15.88% |
| 2017-06-30 | $15.10M | - |
| 2017-03-31 | $15.10M | - |
Sutro Biopharma generated $13.01M in revenue during Q1 2024, up -88.56% compared to the previous quarter, and up 150.70% compared to the same period a year ago.
Sutro Biopharma Revenue Breakdown
Sutro Biopharma Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 18 |
|---|---|
| Other Revenue | $5.42M |
| Collaboration Revenue | $13.54M |
Sutro Biopharma's latest annual revenue breakdown by segment (product or service), as of Dec 18: Collaboration Revenue (71.40%), and Other Revenue (28.60%).
Quarterly Revenue by Product
| Product/Service | Dec 18 | Sep 18 |
|---|---|---|
| Other Revenue | $654.00K | $912.00K |
| Collaboration Revenue | $18.43M | - |
Sutro Biopharma's latest quarterly revenue breakdown by segment (product or service), as of Dec 18: Collaboration Revenue (96.57%), and Other Revenue (3.43%).
Sutro Biopharma Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 18 |
|---|---|
| Collaboration Revenue | $13.54M |
| Other Revenue | $5.42M |
Sutro Biopharma's latest annual revenue breakdown by geography, as of Dec 18: Collaboration Revenue (71.40%), and Other Revenue (28.60%).
Quarterly Revenue by Country
| Country | Dec 18 | Sep 18 |
|---|---|---|
| Other Revenue | $654.00K | $912.00K |
| Collaboration Revenue | $18.43M | - |
Sutro Biopharma's latest quarterly revenue breakdown by geography, as of Dec 18: Collaboration Revenue (96.57%), and Other Revenue (3.43%).
Sutro Biopharma Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| STRO | Sutro Biopharma | $153.73M | $13.01M |
| MRUS | Merus | $43.95M | $7.33M |
| IDYA | IDEAYA Biosciences | $23.39M | - |
| ANAB | AnaptysBio | $17.16M | $10.97M |
| MGTX | MeiraGTx | $14.02M | $282.00K |
| CNTA | Centessa Pharmaceuticals | $6.88M | - |
| FIXX | Q32 Bio | $1.16M | - |
| KROS | Keros Therapeutics | $151.00K | $83.00K |
| OPT | Opthea | $108.41K | $61.27K |
| PCVX | Vaxcyte | - | - |
| AVTE | Aerovate Therapeutics | - | - |
| REPL | Replimune Group | - | - |
| ELYM | Eliem Therapeutics | - | - |
| SNDX | Syndax Pharmaceuticals | - | $3.50M |
| MLYS | Mineralys Therapeutics | - | - |
| LRMR | Larimar Therapeutics | - | - |
| PRDS | Pardes Biosciences | - | - |
| HLVX | HilleVax | - | - |
| GNTA | Genenta Science S.p.A. | - | - |
STRO Revenue FAQ
What is Sutro Biopharma’s yearly revenue?
Sutro Biopharma's yearly revenue for 2023 was $153.73M, representing an increase of 126.84% compared to 2022. The company's yearly revenue for 2022 was $67.77M, representing an increase of 9.52% compared to 2021. STRO's yearly revenue for 2021 was $61.88M, representing an increase of 44.84% compared to 2020.
What is Sutro Biopharma’s quarterly revenue?
Sutro Biopharma's quarterly revenue for Q1 2024 was $13.01M, a -88.56% decrease from the previous quarter (Q4 2023), and a 2.64% increase year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $113.72M, a 571.95% increase from the previous quarter (Q3 2023), and a 1217.44% increase year-over-year (Q4 2022). STRO's quarterly revenue for Q3 2023 was $16.92M, a 62.54% increase from the previous quarter (Q2 2023), and a -32.70% decrease year-over-year (Q3 2022).
What is Sutro Biopharma’s revenue growth rate?
Sutro Biopharma's revenue growth rate for the last 3 years (2021-2023) was 148.43%, and for the last 5 years (2019-2023) was 259.72%.
What are Sutro Biopharma’s revenue streams?
Sutro Biopharma's revenue streams in c 18 are Other Revenue, and Collaboration Revenue. Other Revenue generated $5.42M in revenue, accounting 28.60% of the company's total revenue Collaboration Revenue generated $13.54M in revenue, accounting 71.40% of the company's total revenue
What is Sutro Biopharma’s main source of revenue?
For the fiscal year ending Dec 18, the largest source of revenue of Sutro Biopharma was Collaboration Revenue. This segment made a revenue of $13.54M, representing 71.40% of the company's total revenue.